Miyako Capital has contributed to a series A round for the cancer vaccine developer, which expanded to Japan last year.
VLP Therapeutics, a US-based cancer vaccine developer, secured $15m yesterday in a series A round that included Miyako Capital, a venture capital vehicle for Kyoto University.
Chemicals producer Konishiyasu and diversified conglomerate Sojitz also participated in the round, as did SK Impact Fund, RJ Fund and private investor Robert Hisaoka, all three of which were identified as existing backers.
VLP’s lead product candidate is a cancer vaccine but it is also working on prophylactic vaccines for malaria, dengue fever and covid-19. It launched a subsidiary in Japan, where most of the series A investors are based, in 2020.
Masayoshi Fujimoto, president and chief executive of Sojitz, said: “I am optimistic that the innovative vaccines now being developed at VLP Therapeutics will make a significant contribution to the treatment of cancer, the prevention of malaria and dengue fever, and the fight against new threats such as covid-19.
“In turn, I believe this will improve health and well-being for all and advance the development of medicine.”
– A version of this article first appeared on our sister site, Global Corporate Venturing.
